- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 241/12 - Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
Patent holdings for IPC class C07D 241/12
Total number of patents in this class: 487
10-year publication summary
|
42
|
44
|
26
|
47
|
33
|
36
|
33
|
36
|
24
|
16
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Semiconductor Energy Laboratory Co., Ltd. | 11475 |
13 |
| Bristol-myers Squibb Company | 4867 |
10 |
| Amgen Inc. | 4106 |
10 |
| Guangzhou Magpie Pharmaceuticals Co., Ltd. | 29 |
10 |
| Abbvie Inc. | 1800 |
8 |
| Merck Sharp & Dohme LLC | 3760 |
8 |
| Calico Life Sciences LLC | 98 |
7 |
| F. Hoffmann-La Roche AG | 7941 |
6 |
| Hoffmann-La Roche Inc. | 3461 |
6 |
| Syngenta Crop Protection AG | 6107 |
6 |
| Massachusetts Institute of Technology | 10102 |
6 |
| The General Hospital Corporation | 4759 |
6 |
| Arcus Biosciences, Inc. | 140 |
6 |
| The Broad Institute, Inc. | 1837 |
6 |
| Nippon Soda Co., Ltd. | 894 |
6 |
| Novartis AG | 10730 |
5 |
| The Regents of the University of California | 20059 |
5 |
| Bayer Pharma AG | 1054 |
5 |
| Novaled GmbH | 447 |
5 |
| Vivace Therapeutics, Inc. | 30 |
5 |
| Other owners | 348 |